Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T26220
|
||||
Target Name |
Somatostatin receptor
|
||||
Target Type |
Clinical Trial
|
||||
Disease | Acromegaly [ICD9: 253; ICD10: E22.0] | ||||
Alzheimer disease [ICD9: 331; ICD10: G30] | |||||
Cognitive disorders [ICD9: 290-294, 294.0, 780.09, 780.9, 780.93; ICD10: F01-F07, F04, F05, R41.3] | |||||
Duodenal ulcers [ICD10: K25-K27] | |||||
HCV infection [ICD9: 070.4, 070.5, 070.70; ICD10: B17.1, B18.2] | |||||
Melanoma [ICD9: 172; ICD10: C43] | |||||
Pain [ICD9: 338, 356.0, 356.8,780; ICD10: G64, G90.0, R52, G89] | |||||
BioChemical Class |
G protein-coupled receptors (GPCR)
|
||||
Drugs and Mode of Action | |||||
Drug(s) | 177Lu-DOTA-octreotate (neuroendocrine tumors), Advanced Accelerator Applications | Drug Info | Phase 3 | Melanoma | [523870] |
177Lu-DOTATATE | Drug Info | Phase 2 | HCV infection | [524302] | |
Edotreotide | Drug Info | Phase 2 | Acromegaly | [521481], [540994] | |
FK-962 | Drug Info | Phase 2 | Alzheimer disease | [521603] | |
Somatoprim | Drug Info | Phase 2 | Acromegaly | [543166], [547415] | |
BIM-23268 | Drug Info | Discontinued in Phase 2 | Acromegaly | [539319], [547475] | |
FK-960 | Drug Info | Discontinued in Phase 2 | Cognitive disorders | [546546] | |
SEGLITIDE | Drug Info | Discontinued in Phase 2 | Pain | [539307], [544698] | |
Modulator | 177Lu-DOTA-octreotate (neuroendocrine tumors), Advanced Accelerator Applications | Drug Info | [532708] | ||
177Lu-DOTATATE | Drug Info | [532708] | |||
BIM-23268 | Drug Info | [1572591] | |||
Edotreotide | Drug Info | [1572591] | |||
FK-960 | Drug Info | ||||
FK-962 | Drug Info | ||||
Ilatreotide | Drug Info | ||||
SEGLITIDE | Drug Info | [544040] | |||
Somatoprim | Drug Info | ||||
References | |||||
Ref 521481 | ClinicalTrials.gov (NCT00006370) Radiolabeled SMT-487 (Yttrium Y 90-DOTA-tyr3-octreotide) in Treating Patients With Refractory Small Cell Lung Cancer or Metastatic Breast Cancer. U.S. National Institutes of Health. | ||||
Ref 521603 | ClinicalTrials.gov (NCT00087724) A Randomized Study to Evaluate FK962 in Subjects With Mild to Moderate Alzheimer's Disease. U.S. National Institutes of Health. | ||||
Ref 523870 | ClinicalTrials.gov (NCT01578239) A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours. U.S. National Institutes of Health. | ||||
Ref 524302 | ClinicalTrials.gov (NCT01860742) Randomized Phase III of PRRT Versus Interferon. U.S. National Institutes of Health. | ||||
Ref 539307 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2051). | ||||
Ref 539319 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2083). | ||||
Ref 540994 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5638). | ||||
Ref 543166 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8487). | ||||
Ref 544698 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000642) | ||||
Ref 546546 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008887) | ||||
Ref 532708 | Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience. Pancreas. 2014 May;43(4):518-25. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.